Ultragenyx Pharmaceutical | RARE - Current Assets


Ultragenyx Pharmaceutical reported $544M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Immunic USD 135.09M 22.75M Sep/2026
Insmed USD 1.71B 72.59M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Kyowa Hakko Kirin JPY 482.59B 35.17B Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026